Aspargo acquires Bandol® Sildenafil Spray, currently

0

Immediate revenue and expanding global footprint

  • Acquisition transforms Aspargo into a revenue-generating company
  • Entry into the European market positions Aspargo to market Sildenafil Oral Spray worldwide

ENGLEWOOD CLIFFS, NJ and BARCELONA, Spain, May 04, 2022 (GLOBE NEWSWIRE) — Aspargo Laboratories, Inc., a private specialty pharmaceutical company focused on bringing to market innovative formulations of leading drugs, today announced the acquisition from the prescription brand BANDOL® (sildenafil oral suspension) from Laboratorios Rubio SA, a specialty pharmaceutical company headquartered in Barcelona, ​​Spain. BANDOL® is indicated for the treatment of erectile dysfunction (ED). Concurrent with the acquisition, Aspargo entered into a distribution agreement with Rubio for the continued marketing and promotion of BANDOL® in Spain and a license and supply agreement with Farmalider, SA (Madrid, Spain) for the supply of BANDOL® to the Spanish market.

“The acquisition of BANDOL® is part of our global growth strategic plan that positions Aspargo as the first to market with an innovative oral spray solution for erectile dysfunction,” said Michael Demurjian, President and CEO of Aspargo. “Using BANDOL® As the first company in Europe, we plan to accelerate the commercialization of Sildenafil Oral Spray in other European countries and globally, subject to regulatory compliance in each country.

BANDOL®, offered in a convenient and discreet dosing container that delivers the equivalent of 12.5 mg per actuation, is manufactured in Spain and is mainly prescribed by primary care physicians and urologists. Originally licensed by Rubio from Farmalider – a pharmaceutical company dedicated to the research, development and manufacturing of pharmaceutical products, and launched by Rubio in 2020 – BANDOL® is the only sildenafil oral spray currently on the global market. The Spanish VIAGRA market®CIALIS®and their generic equivalents were valued at approximately $80 million in 2021 (IQVIA Analytics 2021).

“We are delighted to have entered into this commercial distribution agreement with Aspargo and look forward to working together on other opportunities,” said Pelayo Rubio, CEO of Rubio.

Erectile dysfunction is characterized by persistent difficulty in obtaining and maintaining an erection sufficient for sexual intercourse. Although the prevalence of erectile dysfunction has been shown to increase with age, a recent study conducted by the Sexual Medicine and Andrology Unit of the University of Florence, Italy, showed that erectile dysfunction Erectile dysfunction in younger men is likely to be overlooked and dismissed without proper medical evaluation. .

About Aspargo Laboratories, Inc.

Aspargo Laboratories, Inc., located in Englewood Cliffs, New Jersey, is a commercial-stage specialty pharmaceutical company. Aspargo’s current goal is to market an oral spray formulation of sildenafil citrate, the active ingredient in VIAGRA®. Aspargo is the US and international patent holder of the Sildenafil oral spray from Farmalider, SA of Madrid, Spain (www.farmalider.com). For more information, please visit our website at https://aspargolabs.com/.

About Rubio Laboratories

Laboratorios Rubio is a private pharmaceutical company, headquartered in Spain. The company engages in the development, manufacture, marketing and distribution of established products while introducing new products each year from both proprietary formulations and strategic business partnerships. For more information, please visit our website at https://www.laboratoriosrubio.com/.

Contact:
Aspargo Laboratories, Inc.
(201) 408-4831
[email protected]

Share.

Comments are closed.